Literature DB >> 32839967

Estimation of conditional power for cluster-randomized trials with interval-censored endpoints.

Kaitlyn Cook1, Rui Wang1,2.   

Abstract

Cluster-randomized trials (CRTs) of infectious disease preventions often yield correlated, interval-censored data: dependencies may exist between observations from the same cluster, and event occurrence may be assessed only at intermittent study visits. This data structure must be accounted for when conducting interim monitoring and futility assessment for CRTs. In this article, we propose a flexible framework for conditional power estimation when outcomes are correlated and interval-censored. Under the assumption that the survival times follow a shared frailty model, we first characterize the correspondence between the marginal and cluster-conditional survival functions, and then use this relationship to semiparametrically estimate the cluster-specific survival distributions from the available interim data. We incorporate assumptions about changes to the event process over the remainder of the trial-as well as estimates of the dependency among observations in the same cluster-to extend these survival curves through the end of the study. Based on these projected survival functions, we generate correlated interval-censored observations, and then calculate the conditional power as the proportion of times (across multiple full-data generation steps) that the null hypothesis of no treatment effect is rejected. We evaluate the performance of the proposed method through extensive simulation studies, and illustrate its use on a large cluster-randomized HIV prevention trial.
© 2020 The International Biometric Society.

Entities:  

Keywords:  cluster-randomized trial; conditional power; interim monitoring; interval censoring

Mesh:

Year:  2020        PMID: 32839967      PMCID: PMC8979414          DOI: 10.1111/biom.13360

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   1.701


  18 in total

1.  Estimation of multivariate frailty models using penalized partial likelihood.

Authors:  S Ripatti; J Palmgren
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

Review 2.  A review of methods for futility stopping based on conditional power.

Authors:  John M Lachin
Journal:  Stat Med       Date:  2005-09-30       Impact factor: 2.373

3.  The B-value: a tool for monitoring data.

Authors:  K K Lan; J Wittes
Journal:  Biometrics       Date:  1988-06       Impact factor: 2.571

4.  Comparison of futility monitoring guidelines using completed phase III oncology trials.

Authors:  Qiang Zhang; Boris Freidlin; Edward L Korn; Susan Halabi; Sumithra Mandrekar; James J Dignam
Journal:  Clin Trials       Date:  2016-09-22       Impact factor: 2.486

5.  Sample size considerations in the design of cluster randomized trials of combination HIV prevention.

Authors:  Rui Wang; Ravi Goyal; Quanhong Lei; M Essex; Victor De Gruttola
Journal:  Clin Trials       Date:  2014-06       Impact factor: 2.486

6.  Effects of mid-point imputation on the analysis of doubly censored data.

Authors:  C G Law; R Brookmeyer
Journal:  Stat Med       Date:  1992-09-15       Impact factor: 2.373

7.  Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial.

Authors:  Magali Lemaitre; Thierry Meret; Monique Rothan-Tondeur; Joel Belmin; Jean-Louis Lejonc; Laurence Luquel; François Piette; Michel Salom; Marc Verny; Jean-Marie Vetel; Pierre Veyssier; Fabrice Carrat
Journal:  J Am Geriatr Soc       Date:  2009-08-04       Impact factor: 5.562

8.  Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.

Authors:  E Lesaffre; M J Edelman; N H Hanna; K Park; N Thatcher; S Willemsen; B Gaschler-Markefski; R Kaiser; C Manegold
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

9.  Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana.

Authors:  Joseph Makhema; Kathleen E Wirth; Molly Pretorius Holme; Tendani Gaolathe; Mompati Mmalane; Etienne Kadima; Unoda Chakalisa; Kara Bennett; Jean Leidner; Kutlo Manyake; Atang M Mbikiwa; Selebaleng V Simon; Rona Letlhogile; Kutlwano Mukokomani; Erik van Widenfelt; Sikhulile Moyo; Refeletswe Lebelonyane; Mary G Alwano; Kathleen M Powis; Scott L Dryden-Peterson; Coulson Kgathi; Vlad Novitsky; Janet Moore; Pamela Bachanas; William Abrams; Lisa Block; Shenaaz El-Halabi; Tafireyi Marukutira; Lisa A Mills; Connie Sexton; Elliot Raizes; Simani Gaseitsiwe; Hermann Bussmann; Lillian Okui; Oaitse John; Roger L Shapiro; Sherri Pals; Haben Michael; Michelle Roland; Victor DeGruttola; Quanhong Lei; Rui Wang; Eric Tchetgen Tchetgen; M Essex; Shahin Lockman
Journal:  N Engl J Med       Date:  2019-07-18       Impact factor: 176.079

10.  Designing a stepped wedge trial: three main designs, carry-over effects and randomisation approaches.

Authors:  Andrew J Copas; James J Lewis; Jennifer A Thompson; Calum Davey; Gianluca Baio; James R Hargreaves
Journal:  Trials       Date:  2015-08-17       Impact factor: 2.279

View more
  2 in total

1.  Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters.

Authors:  Victor DeGruttola; Ravi Goyal; Natasha K Martin; Rui Wang
Journal:  Clin Trials       Date:  2022-07-27       Impact factor: 2.599

2.  Interim data monitoring in cluster randomised trials: Practical issues and a case study.

Authors:  K Hemming; J Martin; I Gallos; A Coomarasamy; L Middleton
Journal:  Clin Trials       Date:  2021-06-22       Impact factor: 2.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.